Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Memorial Sloan Kettering Cancer Center
M

Complication of AlloHSCT: Phases of Complications, Classification of GVHD, Ruxolitinib for SR Acute GVHD, Ibrutinib Induces Responses in SR Chronic GVH & Phases of Opportunistic Infections

By Memorial Sloan Kettering Cancer Center FEATURING Miguel-Angel Perales
By Memorial Sloan Kettering Cancer Center FEATURING Miguel-Angel Perales
319 views
March 25, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Hematologic Transplantation and Malignancies
11:20
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Validation of the Composite CR Definitions …

Feat. J. Bewersdorf
11:00
ASH 2022 Conference Coverage

ASH 2022: Management of Accelerated and Blast-Phase MPN

Feat. R. Rampal
23:13
MDS Foundation

MDS Foundation ASH 2021 Review: Towards a Genetically Inspired Class…

Feat. E. Bernard
11:04
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Evaluation of IWG 2006 Response Criteria in Patients with …

Feat. J. Bewersdorf
17:46
2021 International Congress on Myeloproliferative Neoplasms

Which Published Schemas Are Helpful in MPN Transplant Decisions?

Feat. S. Giralt
14:46
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

SOHO 2021 Update on NY-ESO-1 TCR T-Cell Therapy

Feat. A. Schoenfeld
10:40
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

SOHO 2021: A Tumor-Agnostic TCR-Mimic CAR T-Cell Specific for NDC80 …

Feat. M. Klatt
11:24
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

2021 SOHO Highlights on CARs for Solid Tumors

Feat. R. O'Cearbhaill
24:52
SOHO Highlights: State of the Art and Next Questions

CAR-T State of the Art: What Therapies Will Be Available in the Next…

Feat. S. Giralt
18:48
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on CARs: How Does the Ideal Next-Gen CAR T-Cell…

Feat. R. Brentjens
16:23
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on Myelofibrosis: What Is the Distinctive Featu…

Feat. R. Rampal
16:42
University of Miami's 2nd Biennial Miami Leukemia Symposium

IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of R…

Feat. E. Stein
40:55
Memorial Sloan Kettering Cancer Center

Hematopoietic Stem Cell Transplant: Difference Between AutoHSCT and …

Feat. M. Perales
23:23
Memorial Sloan Kettering Cancer Center

Complication of AlloHSCT: Phases of Complications, Classification of…

Feat. M. Perales
17:30
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

CNS Toxicity of CAR-T in Hematologic Malignancies: Clinical Manifest…

Feat. B. Santomasso
65:45
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Setting Up a CAR T Program Ins and Outs: Institutional Program Devel…

Feat. S. Giralt
23:38
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Ongoing Efforts to Improve the Safety of CAR T-Cell Therapy: Cytokin…

Feat. B. Santomasso